MUNICH — Direct oral anticoagulant (DOAC) therapy reduced the risk for adverse clinical events by 69% compared with no anticoagulation in patients with atrial fibrillation (AF) who are at intermediate risk for stroke, according to results of the randomized SINGLE-AF trial. At 24 months, the primary composite endpoint of stroke…
Read More
DOACs Benefit AF Patients With Intermediate Stroke Risk
